Journal Logo

Simultaneous Sessions III: Future implications of management in CML

S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY

Malagola, M.1; Efficace, F.2; Polverelli, N.1; Cottone, F.2; Abruzzese, E.3; Iurlo, A.4; Bucelli, C.4; Stagno, F.5; Bonifacio, M.6; D’Adda, M.7; Lunghi, M.8; Crugnola, M.9; Lunghi, F.10; Castagnetti, F.11; Rosti, G.11; Ferrari, M.L.12; Bergamaschi, M.13; Binotto, G.14; Sancetta, R.15; Coppi, M.R.16; Giai, V.17; Rege Cambrin, G.18; Romano, A.19; Tiribelli, M.20; Russo, S.21; Aprile, L.22; Falcone, A.P.23; Rupoli, S.24; Russo Rossi, A.25; Usala, E.26; Martino, B.27; Gandolfi, L.1; Bernardi, S.1; Zanaglio, C.1; Farina, M.1; Baccarani, M.11; Russo, D.1

Author Information
doi: 10.1097/01.HS9.0000561808.14876.94
  • Free

Abstract

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.